{
  "pmcid": "10492188",
  "sha256": "8478fc0ed3fd5f4017131bebf063330eaefca798356f2ec1b54a230d27a47f74",
  "timestamp_utc": "2025-11-09T23:07:16.479383+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.196337545126358,
    "reading_ease": 39.45883844765345,
    "word_count": 277
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Axillary Lymph Node Dissection Omission in Mastectomy Patients with Sentinel Lymph Node Metastases"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned (1:1)"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with histologically confirmed invasive BC, tumour size ≤5 cm, cN0, and ≤2 metastatic SLNs"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned (1:1) to receive ALND followed by adjuvant treatment (standard arm) or adjuvant treatment alone (experimental arm)"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was overall survival (OS) and the secondary endpoint was recurrence-free survival (RFS), assessed over a median follow-up of 33.0 months"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 218 patients were randomised: 111 to the ALND group and 107 to the SLNB-only group"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "In the intention-to-treat analysis"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "the 5-year OS rates were 97.8% in the ALND arm and 98.7% in the SLNB-only arm (P = 0.597)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "NCT05160324"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}